Verition Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Verition Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-17,500	Closed	-$1.44M	–	3202
2024 Q2	$1.44M	Sell	17,500 -6,400	-27%	-$533K	0.01%	1454
2024 Q1	$2.09M	Buy	23,900 +18,000	+305%	+$1.61M	0.01%	1185
2023 Q4	$569K	Buy	+5,900	New	+$522K	﹤0.01%	1456
2023 Q2	–	Sell	-10,200	Closed	-$992K	–	2219
2023 Q1	$992K	Buy	+10,200	New	+$1.06M	0.01%	955
2021 Q3	–	Sell	-5,000	Closed	-$417K	–	1922
2021 Q2	$417K	Buy	+5,000	New	+$396K	﹤0.01%	1177
2020 Q1	–	Sell	-7,700	Closed	-$651K	–	641
2019 Q4	$651K	Buy	+7,700	New	+$582K	0.01%	579
2019 Q2	–	Sell	-35,900	Closed	-$3.19M	–	1076
2019 Q1	$3.19M	Buy	35,900 +15,500	+76%	+$1.44M	0.12%	115
2018 Q4	$1.74M	Buy	+20,400	New	+$1.94M	0.12%	149

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Verition Fund Management's BMRN Position: Q2 2026 in Review

Verition Fund Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 22,500 shares worth $1.29M. The stake represents 0.01% of the portfolio and ranks #1330 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in BMRN as recently as Q4 2025.

Verition Fund Management first reported a position in BMRN in Q2 2013 and has held it in 39 quarters since. The position peaked at $22M in Q2 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Verition Fund Management held 22,500 shares of BioMarin Pharmaceuticals worth $1.29M as of Q2 2026.
BioMarin Pharmaceuticals was a new Verition Fund Management position in Q2 2026.
BioMarin Pharmaceuticals made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1330 holding.
Verition Fund Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 39 quarters since.
Verition Fund Management's BioMarin Pharmaceuticals position peaked at $22M in Q2 2022.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.